GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Cheng Yi Pharmaceutical Co Ltd (SHSE:603811) » Definitions » ROIC %

Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) ROIC % : 6.89% (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Zhejiang Cheng Yi Pharmaceutical Co ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Zhejiang Cheng Yi Pharmaceutical Co's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2024 was 6.89%.

As of today (2024-05-19), Zhejiang Cheng Yi Pharmaceutical Co's WACC % is 9.40%. Zhejiang Cheng Yi Pharmaceutical Co's ROIC % is 8.42% (calculated using TTM income statement data). Zhejiang Cheng Yi Pharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Zhejiang Cheng Yi Pharmaceutical Co ROIC % Historical Data

The historical data trend for Zhejiang Cheng Yi Pharmaceutical Co's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Cheng Yi Pharmaceutical Co ROIC % Chart

Zhejiang Cheng Yi Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.63 19.57 13.60 10.63 8.80

Zhejiang Cheng Yi Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.40 8.26 4.03 14.16 6.89

Competitive Comparison of Zhejiang Cheng Yi Pharmaceutical Co's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Cheng Yi Pharmaceutical Co's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Cheng Yi Pharmaceutical Co's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Cheng Yi Pharmaceutical Co's ROIC % distribution charts can be found below:

* The bar in red indicates where Zhejiang Cheng Yi Pharmaceutical Co's ROIC % falls into.



Zhejiang Cheng Yi Pharmaceutical Co ROIC % Calculation

Zhejiang Cheng Yi Pharmaceutical Co's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=136.785 * ( 1 - 6.9% )/( (1388.403 + 1507.34)/ 2 )
=127.346835/1447.8715
=8.80 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1719.094 - 151.841 - ( 213.507 - max(0, 257.988 - 436.838+213.507))
=1388.403

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1892.766 - 210.65 - ( 294.141 - max(0, 342.648 - 517.424+294.141))
=1507.34

Zhejiang Cheng Yi Pharmaceutical Co's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2024 is calculated as:

ROIC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=119.196 * ( 1 - 13.08% )/( (1507.34 + 1500.737)/ 2 )
=103.6051632/1504.0385
=6.89 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1892.766 - 210.65 - ( 294.141 - max(0, 342.648 - 517.424+294.141))
=1507.34

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1877.301 - 176.31 - ( 251.963 - max(0, 295.95 - 496.204+251.963))
=1500.737

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Cheng Yi Pharmaceutical Co  (SHSE:603811) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Zhejiang Cheng Yi Pharmaceutical Co's WACC % is 9.40%. Zhejiang Cheng Yi Pharmaceutical Co's ROIC % is 8.42% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Zhejiang Cheng Yi Pharmaceutical Co ROIC % Related Terms

Thank you for viewing the detailed overview of Zhejiang Cheng Yi Pharmaceutical Co's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) Business Description

Traded in Other Exchanges
N/A
Address
No. 118, Chemical Road, Dongtou District, Zhejiang Province, Wenzhou, CHN, 325700
Zhejiang Cheng Yi Pharmaceutical Co Ltd is a pharmaceutical company that produces capsules, injections, tablets, APIs, and pharmaceutical intermediates in China. Its main products include glucosamine hydrochloride raw materials and preparations, torasemide injection and capsules, Gastrodin raw materials, ribavirin and purine raw materials, and so on.

Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) Headlines

No Headlines